Pre-order Enquiry
Request Free Sample
Healthcare
Aerospace & Defence
Agriculture
Automations
Chemicals & Advanced Materials
Food & Beverages
Information & Communication Technology
Oil & Gas
Power & Energy
According to the latest research, the global Dengue Treatment market size was valued at USD 682.86 million in 2022 and is expected to expand at a CAGR of 16.43% during the forecast period, reaching USD 1701.07 million by 2028.
Dengue is a viral disease transmitted by mosquitoes which has spread rapidly in all WHO (World Health Organization) regions in recent years. The dengue virus is mainly transmitted by female mosquitoes from the genus Aedes aegypti and to a lesser degree from Ae. albopictus. The diseases transmitted by these vector mosquitoes are chikungunya, yellow fever and Zika viruses. Dengue is prevalent in the tropics, induced by precipitation, temperature, relative humidity and unplanned rapid urbanization with local risk variability. Symptoms of dengue include fever, headache vomiting, muscle, joint pain, and characteristic skin rash. The patient recovers from dengue within seven days; however, in some cases, it can develop into life-threatening dengue hemorrhagic fever. The global dengue treatment market is anticipated grow due to the rise in the burden of dengue in tropical and subtropical regions. Increase in government funding to fight against dengue and unmet market needs of managing this burden globally boosts the dengue treatment market.
Influence of COVID-19 Outbreak on Dengue Treatment Industry Development
While the world battles to wrestle with the impact of the COVID-19 pandemic, regions with endemic dengue fever are confronting the possibility of a double pandemic that could completely overpower health care services administrations. Dengue viruses and the virus that causes COVID-19 virus cause similar symptoms in the early stages. So, most of the people are confusing it to be dengue at getting themselves tested for dengue too. Simultaneous outbreaks of dengue and COVID-19, as well as probable cases of overlapping infections, have already started in Latin America and certain Asian countries. The challenge of the COVID-19 pandemic threatens to undermine, actions to limit other dengue epidemics.
Overall, co-infection of dengue and COVID-19 is raising complications, and to tackle this unusual scenario which might turn fatal, the governmental bodies are introducing mass vaccination programs, whereas healthcare providers are using balanced tactics to manage both the conditions at once. Precise epidemiological and contact history-taking joined with due attention to false-positive dengue serology and the chance of co-infections are key devices for frontline doctors to overcome this almost insurmountable challenge.
Drivers
In terms of region, the global dengue treatment market has been divided into North America, Europe, Southeast Asia, South Asia, Latin America, and Middle East & Africa. South Asia dominated the global dengue treatment market in 2020.South Asia’s significant market share can be ascribed to presence of a large number of key players, rise in prevalence of dengue, improving healthcare infrastructure, and funding from governments and large corporates. India and Bengal are the leading markets in the region, due to the rise in investment in development of well-equipped health care institutions and rise in prevalence of dengue cases.
Moreover, the recent dengue outbreak in various regions in South Asia indicates that there may be increased risks for future dengue outbreaks in these countries, due to the influx of dengue viruses from overseas combined with the increase in vector population and the expansion of the habitats caused by climate changes, resulting in the rising cases of dengue in South Asia. According to a report published by the Directorate of National Vector Borne Disease Control Program 2019, a total of 67,377 cases of dengue and 48 deaths due to the vector-borne disease have been reported from across India as of October 2019. Thus, considering all the above-mentioned factors, as the number of patients is rising in this region, the testing of the dengue is also expected to rise and boost the growth of the dengue treatment market.
The market is driven by factors such as growing awareness about prevention and control of dengue, robust promising pipeline of manufacturers for dengue treatment, increasing prevalence of dengue, continuous research, and development of dengue vaccine. In spite of the controlled steps, the global increase in dengue incidence, along with the increased frequency of localized outbreaks and the potential of aedes species to flourish lead to increase in consumption of the treatment option for dengue treatment and is expected to act as a driver for the dengue treatment market.
In addition, market players keen interest in uplift the market by partnerships, promising dengue pipelines and rise in medical insurance in developing countries is anticipated to drive the market furthermore. Rising R&D investment and activities is expected to create lucrative opportunities in the market.
Region Overview:
South Asia had the highest growth rate of all regions.
Company Overview:
Pfizer Inc. is one of the major players operating in the Dengue Treatment market, holding a share of 13.76% in 2021.
Pfizer Inc. is an American multinational pharmaceutical and biotechnology corporation headquartered on 42nd Street in Manhattan, New York City. Pfizer develops and produces medicines and vaccines for immunology, oncology, cardiology, endocrinology, and neurology. The company has several blockbuster drugs or products.
GlaxoSmithKline plc helps improve the health of millions of people around the world by discovering, developing and manufacturing innovative medicines, vaccines and consumer healthcare products. GlaxoSmithKline plc’s Pharmaceuticals business has a broad portfolio of innovative and established medicines in respiratory, HIV, immuno-inflammation and oncology.
Segmentation Overview:
Among different product types, Vaccination segment is anticipated to contribute the largest market share in 2027.
Application Overview:
By application, the Hospitals segment occupied the biggest share from 2017 to 2022.
This report elaborates on the market size, market characteristics, and market growth of the Dengue Treatment industry between the year 2018 to 2028, and breaks down according to the product type, downstream application, and consumption area of Dengue Treatment. The report also introduces players in the industry from the perspective of the value chain and looks into the leading companies.
Key Points this Global Dengue Treatment Market Report Include:
Market Size Estimates: Dengue Treatment market size estimation in terms of revenue and sales from 2018-2028
Market Dynamic and Trends: Dengue Treatment market drivers, restraints, opportunities, and challenges
Macro-economy and Regional Conflict: Influence of global inflation and Russia & Ukraine War on the Dengue Treatment market
Segment Market Analysis: Dengue Treatment market revenue and sales by type and by application from 2018-2028
Regional Market Analysis: Dengue Treatment market situations and prospects in major and top regions and countries
Dengue Treatment Market
Dengue Treatment Industry Chain: Dengue Treatment market raw materials & suppliers, manufacturing process, distributors by region, downstream customers
Dengue Treatment Industry News, Policies by regions
Dengue Treatment Industry Porters Five Forces Analysis
Key players in the global Dengue Treatment market are covered in Chapter 2:
Fresenius Kabi USA
Aurobindo Pharma
Sun Pharmaceutical Industries Ltd.
Teva Pharmaceuticals
Hikma Pharmaceuticals PLC
Baxter
Dr. Reddy’s Laboratories Limited
Pfizer Inc.
Takeda Pharmaceutical Company Limited
Sanofi
Mylan N.V
Perrigo Company plc
GlaxoSmithKline plc
In Chapter 6 and Chapter 9, on the basis of types, the Dengue Treatment market from 2018 to 2028 is primarily split into:
Medication
Supportive Care
Vaccination
Others
In Chapter 7 and Chapter 10, on the basis of applications, the Dengue Treatment market from 2018 to 2028 covers:
Hospitals
Specialty Clinics
Home Healthcare
Others
Geographically, the detailed analysis of consumption, revenue, market share and growth rate of the following regions from 2018 to 2028 are covered in Chapter 8 and Chapter 11:
United States
Europe
China
Japan
India
Southeast Asia
Latin America
Middle East and Africa
Others
In summary, this report relies on sources from both primary and secondary, combines comprehensive quantitative analysis with detailed qualitative analysis, and pictures the market from a macro overview to micro granular segment aspects. Whatever your role in this industry value chain is, you should benefit from this report with no doubt.
Chapter Outline
This report consists of 12 chapters. Below is a brief guideline to help you quickly grasp the main contents of each chapter:
Chapter 1 first introduces the product overview, market scope, product classification, application, and regional division, and then summarizes the global Dengue Treatment market size in terms of revenue, sales volume, and average price.
Chapter 2 analyzes the main companies in the Dengue Treatment industry, including their main businesses, products/services, sales, prices, revenue, gross profit margin, and the latest developments/updates.
Chapter 3 is an analysis of the competitive environment of Dengue Treatment market participants. This mainly includes the revenue, sales, market share, and average price of the top players, along with the market concentration ratio in 2022 and the players' M&A and expansion in recent years.
Chapter 4 is an analysis of the Dengue Treatment industrial chain, including raw material analysis, manufacturing cost structure, distributors, and major downstream buyers.
Chapter 5 focuses on Dengue Treatment market dynamics and marketing strategy analysis, which include opportunities, challenges, industry development trends under inflation, industry news and policies analyzed by region, Porter's Five Forces analysis, as well as direct and indirect marketing, and the development trends of marketing channels.
Chapters 6-8 have segmented the Dengue Treatment market by type, application, and region, with a focus on sales and value from 2018 to 2023 from both vertical and horizontal perspectives.
Chapters 9-11 provide detailed Dengue Treatment market forecast data for 2023-2028, broken down by type and application, region, and major countries to help understand future growth trends.
Chapter 12 concludes with an explanation of the data sources and research methods. Verify and analyze through preliminary research to obtain final quantitative and qualitative data.
2022
Dengue is a viral disease transmitted by mosquitoes which has spread rapidly in all WHO (World Health Organization) regions in recent years. The dengue virus is mainly transmitted by female mosquitoes from the genus Aedes aegypti and to a lesser degree from Ae. albopictus. The diseases transmitted by these vector mosquitoes are chikungunya, yellow fever and Zika viruses. Dengue is prevalent in the tropics, induced by precipitation, temperature, relative humidity and unplanned rapid urbanization with local risk variability. Symptoms of dengue include fever, headache vomiting, muscle, joint pain, and characteristic skin rash. The patient recovers from dengue within seven days; however, in some cases, it can develop into life-threatening dengue hemorrhagic fever. The global dengue treatment market is anticipated grow due to the rise in the burden of dengue in tropical and subtropical regions. Increase in government funding to fight against dengue and unmet market needs of managing this burden globally boosts the dengue treatment market.
Influence of COVID-19 Outbreak on Dengue Treatment Industry Development
While the world battles to wrestle with the impact of the COVID-19 pandemic, regions with endemic dengue fever are confronting the possibility of a double pandemic that could completely overpower health care services administrations. Dengue viruses and the virus that causes COVID-19 virus cause similar symptoms in the early stages. So, most of the people are confusing it to be dengue at getting themselves tested for dengue too. Simultaneous outbreaks of dengue and COVID-19, as well as probable cases of overlapping infections, have already started in Latin America and certain Asian countries. The challenge of the COVID-19 pandemic threatens to undermine, actions to limit other dengue epidemics.
Overall, co-infection of dengue and COVID-19 is raising complications, and to tackle this unusual scenario which might turn fatal, the governmental bodies are introducing mass vaccination programs, whereas healthcare providers are using balanced tactics to manage both the conditions at once. Precise epidemiological and contact history-taking joined with due attention to false-positive dengue serology and the chance of co-infections are key devices for frontline doctors to overcome this almost insurmountable challenge.
Drivers
In terms of region, the global dengue treatment market has been divided into North America, Europe, Southeast Asia, South Asia, Latin America, and Middle East & Africa. South Asia dominated the global dengue treatment market in 2020.South Asia’s significant market share can be ascribed to presence of a large number of key players, rise in prevalence of dengue, improving healthcare infrastructure, and funding from governments and large corporates. India and Bengal are the leading markets in the region, due to the rise in investment in development of well-equipped health care institutions and rise in prevalence of dengue cases.
Moreover, the recent dengue outbreak in various regions in South Asia indicates that there may be increased risks for future dengue outbreaks in these countries, due to the influx of dengue viruses from overseas combined with the increase in vector population and the expansion of the habitats caused by climate changes, resulting in the rising cases of dengue in South Asia. According to a report published by the Directorate of National Vector Borne Disease Control Program 2019, a total of 67,377 cases of dengue and 48 deaths due to the vector-borne disease have been reported from across India as of October 2019. Thus, considering all the above-mentioned factors, as the number of patients is rising in this region, the testing of the dengue is also expected to rise and boost the growth of the dengue treatment market.
The market is driven by factors such as growing awareness about prevention and control of dengue, robust promising pipeline of manufacturers for dengue treatment, increasing prevalence of dengue, continuous research, and development of dengue vaccine. In spite of the controlled steps, the global increase in dengue incidence, along with the increased frequency of localized outbreaks and the potential of aedes species to flourish lead to increase in consumption of the treatment option for dengue treatment and is expected to act as a driver for the dengue treatment market.
In addition, market players keen interest in uplift the market by partnerships, promising dengue pipelines and rise in medical insurance in developing countries is anticipated to drive the market furthermore. Rising R&D investment and activities is expected to create lucrative opportunities in the market.
Major players
in the market are launching their products in emerging markets, instead of opting for developed markets.Region Overview:
South Asia had the highest growth rate of all regions.
Company Overview:
Pfizer Inc. is one of the major players operating in the Dengue Treatment market, holding a share of 13.76% in 2021.
Pfizer Inc. is an American multinational pharmaceutical and biotechnology corporation headquartered on 42nd Street in Manhattan, New York City. Pfizer develops and produces medicines and vaccines for immunology, oncology, cardiology, endocrinology, and neurology. The company has several blockbuster drugs or products.
GlaxoSmithKline plc helps improve the health of millions of people around the world by discovering, developing and manufacturing innovative medicines, vaccines and consumer healthcare products. GlaxoSmithKline plc’s Pharmaceuticals business has a broad portfolio of innovative and established medicines in respiratory, HIV, immuno-inflammation and oncology.
Segmentation Overview:
Among different product types, Vaccination segment is anticipated to contribute the largest market share in 2027.
Application Overview:
By application, the Hospitals segment occupied the biggest share from 2017 to 2022.
This report elaborates on the market size, market characteristics, and market growth of the Dengue Treatment industry between the year 2018 to 2028, and breaks down according to the product type, downstream application, and consumption area of Dengue Treatment. The report also introduces players in the industry from the perspective of the value chain and looks into the leading companies.
Key Points this Global Dengue Treatment Market Report Include:
Market Size Estimates: Dengue Treatment market size estimation in terms of revenue and sales from 2018-2028
Market Dynamic and Trends: Dengue Treatment market drivers, restraints, opportunities, and challenges
Macro-economy and Regional Conflict: Influence of global inflation and Russia & Ukraine War on the Dengue Treatment market
Segment Market Analysis: Dengue Treatment market revenue and sales by type and by application from 2018-2028
Regional Market Analysis: Dengue Treatment market situations and prospects in major and top regions and countries
Dengue Treatment Market
Competitive Landscape
and Major Players: Analysis of 10-15 leading market players, sales, price, revenue, gross, gross margin, product/service profile and recent development/updates, etc.Dengue Treatment Industry Chain: Dengue Treatment market raw materials & suppliers, manufacturing process, distributors by region, downstream customers
Dengue Treatment Industry News, Policies by regions
Dengue Treatment Industry Porters Five Forces Analysis
Key players in the global Dengue Treatment market are covered in Chapter 2:
Fresenius Kabi USA
Aurobindo Pharma
Sun Pharmaceutical Industries Ltd.
Teva Pharmaceuticals
Hikma Pharmaceuticals PLC
Baxter
Dr. Reddy’s Laboratories Limited
Pfizer Inc.
Takeda Pharmaceutical Company Limited
Sanofi
Mylan N.V
Perrigo Company plc
GlaxoSmithKline plc
In Chapter 6 and Chapter 9, on the basis of types, the Dengue Treatment market from 2018 to 2028 is primarily split into:
Medication
Supportive Care
Vaccination
Others
In Chapter 7 and Chapter 10, on the basis of applications, the Dengue Treatment market from 2018 to 2028 covers:
Hospitals
Specialty Clinics
Home Healthcare
Others
Geographically, the detailed analysis of consumption, revenue, market share and growth rate of the following regions from 2018 to 2028 are covered in Chapter 8 and Chapter 11:
United States
Europe
China
Japan
India
Southeast Asia
Latin America
Middle East and Africa
Others
In summary, this report relies on sources from both primary and secondary, combines comprehensive quantitative analysis with detailed qualitative analysis, and pictures the market from a macro overview to micro granular segment aspects. Whatever your role in this industry value chain is, you should benefit from this report with no doubt.
Chapter Outline
This report consists of 12 chapters. Below is a brief guideline to help you quickly grasp the main contents of each chapter:
Chapter 1 first introduces the product overview, market scope, product classification, application, and regional division, and then summarizes the global Dengue Treatment market size in terms of revenue, sales volume, and average price.
Chapter 2 analyzes the main companies in the Dengue Treatment industry, including their main businesses, products/services, sales, prices, revenue, gross profit margin, and the latest developments/updates.
Chapter 3 is an analysis of the competitive environment of Dengue Treatment market participants. This mainly includes the revenue, sales, market share, and average price of the top players, along with the market concentration ratio in 2022 and the players' M&A and expansion in recent years.
Chapter 4 is an analysis of the Dengue Treatment industrial chain, including raw material analysis, manufacturing cost structure, distributors, and major downstream buyers.
Chapter 5 focuses on Dengue Treatment market dynamics and marketing strategy analysis, which include opportunities, challenges, industry development trends under inflation, industry news and policies analyzed by region, Porter's Five Forces analysis, as well as direct and indirect marketing, and the development trends of marketing channels.
Chapters 6-8 have segmented the Dengue Treatment market by type, application, and region, with a focus on sales and value from 2018 to 2023 from both vertical and horizontal perspectives.
Chapters 9-11 provide detailed Dengue Treatment market forecast data for 2023-2028, broken down by type and application, region, and major countries to help understand future growth trends.
Chapter 12 concludes with an explanation of the data sources and research methods. Verify and analyze through preliminary research to obtain final quantitative and qualitative data.
Years considered for this report:
Historical Years:
2018-2022Base Year:
2022Estimated Year:
2023Forecast Period:
2023-2028Frequently Asked Questions
This market study covers the global and regional market with an in-depth analysis of the overall growth prospects in the market. Furthermore, it sheds light on the comprehensive competitive landscape of the global market. The report further offers a dashboard overview of leading companies encompassing their successful marketing strategies, market contribution, recent developments in both historic and present contexts.
- By product type
- By End User/Applications
- By Technology
- By Region
The report provides a detailed evaluation of the market by highlighting information on different aspects which include drivers, restraints, opportunities, and threats. This information can help stakeholders to make appropriate decisions before investing.
